Eliglustat tartrate: Additional Phase II data

Three-year data from an open-label, international Phase II trial in 19 evaluable patients showed that oral eliglustat decreased spleen and liver volumes from baseline

Read the full 247 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE